发布求助
文献互助 智能选刊 最新文献

Heart International最新文献

筛选
英文 中文
Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy. 帕西兰治疗转甲状腺素介导的淀粉样变性合并心肌病。
IF 0.2
Heart International Pub Date : 2023-01-01 DOI: 10.17925/HI.2023.17.1.27
Adam Ioannou, Marianna Fontana, Julian D Gillmore
{"title":"Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy.","authors":"Adam Ioannou,&nbsp;Marianna Fontana,&nbsp;Julian D Gillmore","doi":"10.17925/HI.2023.17.1.27","DOIUrl":"https://doi.org/10.17925/HI.2023.17.1.27","url":null,"abstract":"<p><p>Transthyretin (TTR) is a tetrameric protein, synthesized primarily by the liver, that acts as a physiological transport protein for retinol and thyroxine. TTR can misfold into pathogenic amyloid fibrils that deposit in the heart and nerves, causing a life-threatening transthyretin amyloidosis cardiomyopathy (ATTR-CM), and a progressive and debilitating polyneuropathy (ATTR-PN). Recent therapeutic advances have resulted in the development of drugs that reduce TTR production. Patisiran is a small interfering RNA that disrupts the complimentary mRNA and inhibits TTR synthesis, and is the first gene-silencing medication licensed for the treatment of ATTR amyloidosis. After encouraging results following the use of patisiran for the treatment of patients with ATTR-PN, there has been increasing interest in the use of patisiran for the treatment of ATTR-CM. Various studies have demonstrated improvements across a wide range of cardiac biomarkers following treatment with patisiran, and have changed the perception of ATTR-CM from being thought of as a terminal disease process, to now being regarded as a treatable disease. These successes represent a huge milestone and have the potential to revolutionize the landscape of treatment for ATTR-CM. However, the long-term safety of patisiran and how best to monitor cardiac response to treatment remain to be determined.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"17 1","pages":"27-35"},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339464/pdf/touchcardio-17-1-27.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9879971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock and Hyperkalaemia Syndrome Involving Digoxin Toxicity: A Case Report. 地高辛毒性引起的心动过缓、肾功能衰竭、房室结阻滞、休克和高钾血症综合征1例报告。
IF 0.2
Heart International Pub Date : 2023-01-01 DOI: 10.17925/HI.2023.17.1.60
Meet Shah, Arthi Palani, Ashkan Hashemi, Jaewook Shin
{"title":"Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock and Hyperkalaemia Syndrome Involving Digoxin Toxicity: A Case Report.","authors":"Meet Shah,&nbsp;Arthi Palani,&nbsp;Ashkan Hashemi,&nbsp;Jaewook Shin","doi":"10.17925/HI.2023.17.1.60","DOIUrl":"https://doi.org/10.17925/HI.2023.17.1.60","url":null,"abstract":"<p><p>Bradycardia, renal failure, atrioventricular nodal blockade, shock and hyperkalemia (BRASH) syndrome is named after the pentad of symptoms experienced by patients with this clinical entity, and is propagated via a synergistic mechanism. Herein, we describe a case of an 81-year-old male who presented with bradycardia, dyspnoea on exertion, and confusion. He was also initially found to be in cardiogenic shock. In a setting of elevated digoxin levels, acute renal failure and hyperkalemia, he was diagnosed with BRASH syndrome. Prompt interventions of continuous renal replacement therapy and digoxin antibody administration were performed to treat this patient. His renal function improved and his hyperkalemia and bradycardia resolved over the course of 4 days, and the patient was discharged to a subacute rehabilitation facility after stabilization. BRASH syndrome is a clinical entity requiring prompt diagnosis for life-saving treatment, including renal replacement therapy, vasoactive medications, transvenous pacing, and reversing agents, when appropriate.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"17 1","pages":"60-62"},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339457/pdf/touchcardio-17-1-60.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9825892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy. 马伐卡坦:肥厚性心肌病患者鼻中隔缩小治疗的替代方案。
IF 0.2
Heart International Pub Date : 2023-01-01 DOI: 10.17925/HI.2023.17.1.2
Milind Y Desai, Adel Hajj Ali
{"title":"Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy.","authors":"Milind Y Desai,&nbsp;Adel Hajj Ali","doi":"10.17925/HI.2023.17.1.2","DOIUrl":"https://doi.org/10.17925/HI.2023.17.1.2","url":null,"abstract":"<p><p>Hypertrophic cardiomyopathy (HCM) is a common heridetary cardiac disorder characterized by a wide range of symptoms. The pharmacological treatment of HCM is currently limited to beta blockers, non-dihydropyridine calcium channel blockers and disopyramide. Mavacamten is a novel cardiac myosin inhibitor, which was recently added to the limited pharmacological list of treatment options for HCM. This editorial elaborates on current evidence evaluating the use of mavacamten in patients with symptomatic obstructive HCM, comments on its current use and its expanded potential applications in the future.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"17 1","pages":"2-4"},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339467/pdf/touchcardio-17-1-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9828386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Balloon Aortic Valvuloplasty in the Transcatheter Aortic Valve Implantation Era. 经导管主动脉瓣植入时代的球囊主动脉瓣成形术。
IF 0.2
Heart International Pub Date : 2023-01-01 DOI: 10.17925/HI.2023.17.1.13
Gustavo Arturo Samaja
{"title":"Balloon Aortic Valvuloplasty in the Transcatheter Aortic Valve Implantation Era.","authors":"Gustavo Arturo Samaja","doi":"10.17925/HI.2023.17.1.13","DOIUrl":"https://doi.org/10.17925/HI.2023.17.1.13","url":null,"abstract":"<p><p>As the population continues to grow, and life expectancy has increased, aortic stenosis (AS) has become the most common valvular disease requiring surgical treatment. The evolution of valve replacement therapies has progressed significantly since 1960. In the last 20 years, transcatheter aortic valve implantation (TAVI) has been a game changer, and has potential to become the standard of care. Despite uncertain prognosis benefits, balloon aortic valvuloplasty (BAV) can be useful in a broad range of patients with AS, as well as being a bridging therapy to valve replacement, or as a destination therapy, besides its role in TAVI procedures. This review describes the contemporary role of BAV in AS treatment, and focuses on technical improvements that reframe BAV as an effective tool in a variety of clinical scenarios. One of these improvements is transradial BAV, either with the conventional approach of BAV or applying the bilateral technique with two balloons.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"17 1","pages":"13-18"},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339465/pdf/touchcardio-17-1-13.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9828390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Can Percutaneous Coronary Intervention Revive a Failing Heart? 经皮冠状动脉介入治疗能否挽救衰竭的心脏？
IF 1.9
Heart International Pub Date : 2022-12-21 eCollection Date: 2022-01-01 DOI: 10.17925/HI.2022.16.2.72
Saad M Ezad, Matthew Ryan, Divaka Perera
{"title":"Can Percutaneous Coronary Intervention Revive a Failing Heart?","authors":"Saad M Ezad, Matthew Ryan, Divaka Perera","doi":"10.17925/HI.2022.16.2.72","DOIUrl":"10.17925/HI.2022.16.2.72","url":null,"abstract":"<p><p>Coronary artery disease (CAD) remains the most common cause of heart failure with reduced ejection fraction; despite its prevalence, there is limited evidence to guide physicians in managing patients with CAD with percutaneous revascularization. The REVIVED-BCIS2 trial (ClinicalTrials.gov identifier: NCT01920048) represents the first randomized trial to assess the value of percutaneous coronary intervention in addition to optimal medical therapy in patients with ischaemic left ventricular systolic dysfunction and stable CAD. In this article, we review the results of the REVIVED-BCIS2 trial and compare them to the ClinicalTrials.gov Identifier: NCT00023595 trial (ClinicalTrials.gov Identifier: NCT00023595), which investigated the benefit of surgical revascularization on such patients. Finally, we suggest a pathway for physicians managing patients with ischaemic left ventricular systolic dysfunction based on the current evidence and highlight potential avenues for future research.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"72-74"},"PeriodicalIF":1.9,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872779/pdf/heart-int-16-72.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9213135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Endothelial Adhesion Molecules on Atrial Fibrillation: A Systematic Review and Meta-analysis. 内皮黏附分子对心房颤动的影响：系统回顾与元分析》。
IF 1.9
Heart International Pub Date : 2022-08-31 eCollection Date: 2022-01-01 DOI: 10.17925/HI.2022.16.2.75
Mehran Rahimi, Leili Faridi, Leila Nikniaz, Sara Daneshvar, Amirreza Naseri, Mohammadreza Taban-Sadeghi, Hesam Manaflouyan, Javad Shahabi, Nizal Sarrafzadegan
{"title":"Effect of Endothelial Adhesion Molecules on Atrial Fibrillation: A Systematic Review and Meta-analysis.","authors":"Mehran Rahimi, Leili Faridi, Leila Nikniaz, Sara Daneshvar, Amirreza Naseri, Mohammadreza Taban-Sadeghi, Hesam Manaflouyan, Javad Shahabi, Nizal Sarrafzadegan","doi":"10.17925/HI.2022.16.2.75","DOIUrl":"10.17925/HI.2022.16.2.75","url":null,"abstract":"<p><p><b>Background</b>: Endothelial adhesion molecules (EAMs), and more specifically vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), belong to a family of immunoglobulin-like molecules and are found to have increased expression in inflamed microvessels. Due to the growing evidence regarding EAM effects on cardiovascular diseases, we aimed to investigate the link between EAMs and atrial fibrillation (AF) to discover the efficacy of EAMs assessment as predictive markers in high-risk patients. <b>Methods</b>: We searched for articles published from January 1990 to April 2022. Two independent researchers selected studies that examined the relationship between VCAM-1 and ICAM-1 levels and AF. Study design, patient characteristics, VCAM-1 and ICAM-1 levels, and measurement methods were extracted from the selected articles. <b>Results</b>: Of 181 records, 22 studies were finally included in the systematic review. Meta-analyses showed a significant difference in serum levels of EAMs in patients with AF compared with patients with sinus rhythms (VCAM-1: mean difference [MD] 86.782, 95% CI 22.805-150.758, p=0.008; ICAM-1: MD 28.439 ng/mL, 95% CI 12.540-44.338, p<0.001). In subgroup analysis of persistent AF, the differences were still significant (VCAM-1: MD 98.046, 95% CI 26.582-169.510, p=0.007; ICAM-1: MD 25.091, 95% CI 12.952-37.230, p<0.001). We also found the mean ranges of VCAM-1 (95% CI 661.394-927.984 ng/mL) and ICAM-1 (95% CI 190.101-318.169 ng/mL) in patients with AF. <b>Conclusion</b>: This study suggests a positive association between serum levels of VCAM-1 and ICAM-1 with AF, but there is a need for further large-scale studies.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"75-84"},"PeriodicalIF":1.9,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872785/pdf/heart-int-16-75.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10716071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vasospastic Angina: A Contemporary Review of its Pathophysiology, Diagnosis and Management. 血管痉挛性心绞痛：血管痉挛性心绞痛：病理生理学、诊断和治疗的当代回顾》。
IF 0.2
Heart International Pub Date : 2022-07-26 eCollection Date: 2022-01-01 DOI: 10.17925/HI.2022.16.2.99
Aish Sinha, Haseeb Rahman, Divaka Perera
{"title":"Vasospastic Angina: A Contemporary Review of its Pathophysiology, Diagnosis and Management.","authors":"Aish Sinha, Haseeb Rahman, Divaka Perera","doi":"10.17925/HI.2022.16.2.99","DOIUrl":"10.17925/HI.2022.16.2.99","url":null,"abstract":"<p><p>Nearly 40% of patients presenting to the catheter laboratory with angina have non-obstructed coronary arteries (ANOCA), an umbrella term that encompasses distinct pathophysiological entities, such as coronary artery spasm. Coronary artery spasm leads to sudden reversible coronary flow attenuation, which clinically manifests as vasospastic angina (VSA). VSA is associated with poor quality of life and an increased risk of major adverse cardiac events. However, the pathophysiological mechanisms underlying this phenomenon are incompletely understood, which has resulted in limited therapeutic options for patients afflicted with this condition. The past decade has seen a surge in new research being conducted in the field of ANOCA and VSA. This review article provides a comprehensive summary of the underlying pathophysiological mechanisms of VSA and the current therapeutic options. We also appraise the current diagnostic approach in patients with suspected VSA.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"99-104"},"PeriodicalIF":0.2,"publicationDate":"2022-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872780/pdf/heart-int-16-99.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10772817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid Atrial Fibrillation in the Emergency Department. 急诊科的快速心房颤动
IF 0.2
Heart International Pub Date : 2022-06-30 eCollection Date: 2022-01-01 DOI: 10.17925/HI.2022.16.1.12
Mochamad Yusuf Alsagaff, Hendri Susilo, Christian Pramudia, Dafsah Arifa Juzar, Muhammad Rafdi Amadis, Rerdin Julario, Sunu Budhi Raharjo, Budi Baktijasa Dharmadjati, Terrence Timothy Evan Lusida, Yusuf Azmi, Pieter Afm Doevendans
{"title":"Rapid Atrial Fibrillation in the Emergency Department.","authors":"Mochamad Yusuf Alsagaff,&nbsp;Hendri Susilo,&nbsp;Christian Pramudia,&nbsp;Dafsah Arifa Juzar,&nbsp;Muhammad Rafdi Amadis,&nbsp;Rerdin Julario,&nbsp;Sunu Budhi Raharjo,&nbsp;Budi Baktijasa Dharmadjati,&nbsp;Terrence Timothy Evan Lusida,&nbsp;Yusuf Azmi,&nbsp;Pieter Afm Doevendans","doi":"10.17925/HI.2022.16.1.12","DOIUrl":"https://doi.org/10.17925/HI.2022.16.1.12","url":null,"abstract":"<p><p>Atrial fibrillation (AF) is the most common rhythm disorder seen in doctors' offices and emergency departments (EDs). In both settings, an AF holistic pathway including anticoagulation or stroke avoidance, better symptom management, and cardiovascular and comorbidity optimization should be followed. However, other considerations need to be assessed in the ED, such as haemodynamic instability, the onset of AF, the presence of acute heart failure and pre-excitation. Although the Advanced Cardiovascular Life Support guidelines (European Society of Cardiology guidelines, Acute Cardiac Care Association/European Heart Rhythm Association position statements) and several recent AF publications have greatly assisted physicians in treating AF with rapid ventricular response in the ED, further practical clinical guidance is required to improve physicians' skill and knowledge in providing the best treatment for patients. Herein, we combine multiple strategies with supporting evidence-based treatment and experiences encountered in clinical practice into practical stepwise approaches. We hope that the stepwise algorithm may assist residents and physicians in managing AF in the ED.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 1","pages":"12-19"},"PeriodicalIF":0.2,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524843/pdf/heart-int-16-12.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40653506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Multimodality Imaging Trials Evaluating the Impact of Omega-3 Fatty Acids on Coronary Artery Plaque Characteristics and Burden. 评估 Omega-3 脂肪酸对冠状动脉斑块特征和负担影响的多模态成像试验。
IF 1.9
Heart International Pub Date : 2022-06-30 eCollection Date: 2022-01-01 DOI: 10.17925/HI.2022.16.1.02
Venkat S Manubolu, Matthew J Budoff, Suvasini Lakshmanan
{"title":"Multimodality Imaging Trials Evaluating the Impact of Omega-3 Fatty Acids on Coronary Artery Plaque Characteristics and Burden.","authors":"Venkat S Manubolu, Matthew J Budoff, Suvasini Lakshmanan","doi":"10.17925/HI.2022.16.1.02","DOIUrl":"10.17925/HI.2022.16.1.02","url":null,"abstract":"<p><p>Treatment of established risk factors, especially low-density lipoprotein (LDL) cholesterol, is the cornerstone of preventing atherosclerotic coronary artery disease. Despite reducing LDL cholesterol, there remains a significant risk of cardiovascular disease. Inflammatory and metabolic pathways contribute to recurrence of cardiovascular events, and are often missed in clinical practice. Eicosapentaenoic acid (EPA) may play a crucial role in reducing residual risk of cardiovascular disease. In this review we discuss the clinical applications of omega-3 fatty acids (OM3FAs), their mechanism of action, the difference between pure EPA and docosahexaenoic acid components, and the latest cardiovascular outcome trials and imaging trials evaluating coronary plaque. PubMed and EMBASE were searched to include all the remarkable clinical trials investigating OM3FAs and cardiovascular disease. Beyond statins, additional medications are required to reduce the risk of cardiovascular disease. EPA has shown cardiovascular benefit in addition to statins in large outcome trials. Additionally, multiple serial-imaging studies have demonstrated benefits on plaque progression and stabilization. Due to its pleotropic properties, icosapent ethyl outperforms other OM3FAs in decreasing cardiovascular disease risk in both patients with and without high triglycerides, and is currently recommended as an adjunct to statins. To further strengthen the current evidence, additional research is required to elucidate the inconsistencies between the effects of pure EPA and EPA plus docosahexaenoic acid.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 1","pages":"2-11"},"PeriodicalIF":1.9,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524586/pdf/heart-int-16-02.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40675560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Hype Surrounding Patent Foramen Ovale Closure and Cryptogenic Stroke: A Walk Through History. 围绕卵圆孔未闭和隐源性中风的炒作:回顾历史。
IF 0.2
Heart International Pub Date : 2022-06-24 eCollection Date: 2022-01-01 DOI: 10.17925/HI.2022.16.1.59
Lekha Racharla, Akhil Kher, Zeel Patel, Theresa Maitz, Bryan Kluck
{"title":"The Hype Surrounding Patent Foramen Ovale Closure and Cryptogenic Stroke: A Walk Through History.","authors":"Lekha Racharla,&nbsp;Akhil Kher,&nbsp;Zeel Patel,&nbsp;Theresa Maitz,&nbsp;Bryan Kluck","doi":"10.17925/HI.2022.16.1.59","DOIUrl":"https://doi.org/10.17925/HI.2022.16.1.59","url":null,"abstract":"<p><p>Cryptogenic stroke (CS) represents one-third of all ischaemic strokes. Studies have shown approximately that half of patients with CS have concomitant patent foramen ovale (PFO), with clear data supporting paradoxical embolization as an aetiology of CS. This article is the first of a multi-part review and will detail the history of PFO closure and the clinical trials that have evaluated the efficacy of PFO device closure. Data favour PFO closure in CS for reducing stroke in appropriate patients and should be considered as a treatment modality.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 1","pages":"59-63"},"PeriodicalIF":0.2,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524620/pdf/heart-int-16-59.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40653512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信